Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trial

R Adams, E Brown, L Brown, R Butler, S Falk, D Fisher, R Kaplan, P Quirke, S Richman, L Samuel, J Seligmann, M Seymour, KK Shiu, H Wasan, Richard Wilson, T Maughan, FOCUS4 Trial Investigators

Research output: Contribution to journalArticlepeer-review

45 Citations (Scopus)
195 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trial'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science